Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Pursuant to Regulation 30 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, we wish to inform that
Dr. Reddy's Laboratories Inc, USA, the wholly owned subsidiary of the Company, has entered into an agreement for sale of all the
issued and outstanding membership interests in its wholly owned subsidiary, Dr. Reddy's Laboratories Louisiana LLC (DRLL), along
with manufacturing facility of DRLL in Shreveport, Louisiana, USA. Consequently, Dr. Reddy's Laboratories Louisiana LLC will cease
to be a wholly owned subsidiary of Dr. Reddy's Laboratories Inc as well as step down wholly owned subsidiary of the Dr. Reddy's
Laboratories Limited.
The details required under Regulation 30 of the
SEBI Listing Regulations, read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above sale is given
in Annexure enclosed herewith.
This is for your information and records.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer, and Head-CSR
Disclosure under Part A Para A(i) of Schedule
III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
| Sl. No | Particulars | Description | ||
| 1 | The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year | The details as per last audited financial statement for the financial year ended March 31, 2024 of Dr. Reddy's Laboratories Louisiana LLC (DRLL) are as hereunder: | ||
| Particulars | Amount (USD) | % of consolidated Income/ Net Worth of the Company | ||
| Turnover | USD 38.91 million (1) | 0.68% (3) | ||
| Net worth | USD 29.49 million (2) | 0.47% (3) |
| 2 | Date on which the agreement for sale has been entered into | January 6, 2025 |
| 3 | The expected date of completion of sale/disposal | By March 18, 2025 |
| 4 | Consideration received from such sale/disposal | USD 1 |
| 5 | Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof | Jaguar Labs Holdings, LLC, a Delaware limited liability company. Jaguar Labs Holdings, LLC does not belong to the promoter/ promoter group/ group companies. |
| 6 | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length" | The transaction is not a related party transaction as Jaguar Labs Holdings, LLC is not a related party to the Company or any of its subsidiaries.. |
| 7 | Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations | No |
| 8 | Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale | Not applicable |